Stock info Agile Therapeutics | Filter  Basic-Info

Agile Therapeutics

The past year yielded positive returns for Agile Therapeutics investors

Over the past year the company' stock lost around 12 percent. Over the period from December 2011 till December 2016 the stock lost on average 0 percent.

Agile Therapeutics's headquarter is based in Princeton. Agile Therapeutics is mostly active in the health care eq. & services sector. Mr. Alfred F. Altomari is leading the company as CEO. The CFO of the company is Mr. Scott M. Coiante. Between 2006 and 2016 the global health care companies gained around 102 percent. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.

Agile Therapeutics didn't pay out any dividends (in the past 5 years).

Healthy financed: not so much debt Agile Therapeutics

At the end of 2015 the American company had a balance sheet of around 50,71 million dollars. At the end of 2015 the total debt positon equaled 20,97 million dollars. This is around 41,35 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around -5. So investors paid -5 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 208,06 million dollars. At the end of 2015 the American company had around 22,02 million stocks listed.

All the annual reports of Agile Therapeutics are available here. More information about Agile Therapeutics can be found it's website. .